O'Donnell R T, Dea G, Meyers F J
Department of Internal Medicine, University of California, Davis Medical Center, Sacramento, USA.
J Immunother Emphasis Tumor Immunol. 1995 Jan;17(1):58-61. doi: 10.1097/00002371-199501000-00007.
This study was undertaken to test the hypothesis that the combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-alpha-2b (INF-alpha) would have a favorable clinical impact on patients with advanced renal cell carcinoma. Fifteen patients were treated with INF-alpha, 5 million U/m2 three times a week and GM-CSF 5 micrograms/kg, subcutaneously, daily. Patients received two consecutive 4-week cycles and then restaged. There were no complete responses, two of 15 partial responses (13%), and 13 of 15 had no response (87%). Biological effects (eosinophilia and leukocytosis) were characteristically observed. The therapy was well tolerated, and most side effects were attributable to INF-alpha. The study failed to show that the addition of GM-CSF to INF-alpha would increase the response rate in patients with metastatic renal cell carcinoma by enhancement of macrophage tumoricidal activity.
本研究旨在检验粒细胞巨噬细胞集落刺激因子（GM-CSF）与α-2b干扰素（INF-α）联合应用对晚期肾细胞癌患者会产生良好临床效果这一假设。15例患者接受INF-α治疗，剂量为500万U/m²，每周3次，GM-CSF剂量为5μg/kg，每日皮下注射。患者接受两个连续的4周疗程，然后重新分期。无完全缓解病例，15例中有2例部分缓解（13%），15例中有13例无反应（87%）。观察到典型的生物学效应（嗜酸性粒细胞增多和白细胞增多）。该治疗耐受性良好，大多数副作用归因于INF-α。该研究未能表明在INF-α基础上加用GM-CSF会通过增强巨噬细胞杀瘤活性来提高转移性肾细胞癌患者的缓解率。
